Nursing care of adverse reactions caused by pd-1/ctla-4 combined immunotherapy in patients with advancedgastric cancer
PD-1/CTLA-4 抗体联合免疫治疗晚期胃癌患者所致不良反应的护理

摘要

目的：针对当前 PD-1/CTLA-4 抗体联合免疫治疗用于晚期胃癌患者的效果开展深入分析，探 讨晚期胃癌患者用药后出现的不良反应及护理措施。方法：选择了 2019 年 9 月 1 日到 2020 年 10 月 1 日在 我科使用 PD-1/CTLA-4 抗体联合免疫治疗的晚期胃癌患者为研究对象，回顾性分析患者在治疗过程中出现 的不良反应，并给予相应的护理措施。结果：在 52 例患者中，经有效的药物治疗和护理干预后，药物不良 反应减轻或消除。结论：PD-1/CTLA-4 联合免疫治疗患者存在一定的不良反应，其直接危害患者身体健康， 应全面评估患者的健康状况和既往病史，密切观察患者出现的不良反应，并积极采取相应的治疗及护理措 施，增强患者的耐受性和依从性，以保证患者能顺利完成用药，达到控制疾病的目的。

Abstract

Objective: to analyze the effect of PD-1/CTLA-4 combined immunotherapy on patients with advanced gastric cancer, and to explore the adverse effects and nursing measures in patients with advanced gastric cancer.
Methods: Patients with advanced gastric cancer diagnosed, treated and nursed in our hospital from september1, 2019 to october1,2020 were selected as the research objects. The adverse effect of patients during treatment were retrospectively analyzed and corresponding nursing measures were given.
Results: after effective drug treatment and nursing intervention, the adverse effect was reduced or eliminated in 52 patients.
Conclusion  : Patients with PD-1/CTLA-4 combined immunotherapy have certain adverse effect, which directly endanger the health of patients. It is necessary to comprehensively evaluate the health status and past medical history of patients, closely observe the adverse effect of patients, and actively take corresponding nursing measures and drug treatment to enhance the tolerance and compliance of patients, so as to ensure that patients can successfully complete the medication.